In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
VolitionRX Ltd (AMEX: VNRX) closed the day trading at $0.42 down -2.49% from the previous closing price of $0.43. In other words, the price has decreased by -$2.49 from its previous closing price. On the day, 0.56 million shares were traded.
Ratios:
For a better understanding of VNRX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.40 and its Current Ratio is at 0.40.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on April 08, 2025, initiated with a Buy rating and assigned the stock a target price of $2.50.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 19 ’25 when Micallef Jacob Vincent bought 50,000 shares for $0.43 per share. The transaction valued at 21,500 led to the insider holds 426,033 shares of the business.
Reynolds Cameron John bought 20,000 shares of VNRX for $8,730 on May 19 ’25. The President and CEO now owns 2,319,222 shares after completing the transaction at $0.44 per share. On Mar 26 ’25, another insider, Reynolds Cameron John, who serves as the President and CEO of the company, bought 181,818 shares for $0.55 each. As a result, the insider paid 100,000 and bolstered with 2,299,222 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 32.97.
Stock Price History:
Over the past 52 weeks, VNRX has reached a high of $0.90, while it has fallen to a 52-week low of $0.42. The 50-Day Moving Average of the stock is -18.07%, while the 200-Day Moving Average is calculated to be -31.19%.
Shares Statistics:
A total of 100.75M shares are outstanding, with a floating share count of 76.34M. Insiders hold about 25.90% of the company’s shares, while institutions hold 20.39% stake in the company.
Earnings Estimates
Its stock is currently analyzed by 4.0 different market analysts. The consensus estimate for the next quarter is -$0.04, with high estimates of -$0.02 and low estimates of -$0.05.
Analysts are recommending an EPS of between -$0.06 and -$0.19 for the fiscal current year, implying an average EPS of -$0.12. EPS for the following year is -$0.03, with 4.0 analysts recommending between $0.09 and -$0.12.
Revenue Estimates
4 analysts predict $425.5k in revenue for the current quarter. It ranges from a high estimate of $600k to a low estimate of $277k. As of the current estimate, VolitionRX Ltd’s year-ago sales were $395.8kFor the next quarter, 4 analysts are estimating revenue of $1.14M. There is a high estimate of $2.41M for the next quarter, whereas the lowest estimate is $550k.
A total of 4 analysts have provided revenue estimates for VNRX’s current fiscal year. The highest revenue estimate was $9.66M, while the lowest revenue estimate was $2M, resulting in an average revenue estimate of $4.96M. In the same quarter a year ago, actual revenue was $1.23MBased on 4 analysts’ estimates, the company’s revenue will be $26.43M in the next fiscal year. The high estimate is $29.26M and the low estimate is $23.65M.
